Literature DB >> 12197897

Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis.

K Kurasawa1, Y Nawata, K Takabayashi, K Kumano, Y Kita, Y Takiguchi, T Kuriyama, M Sueishi, Y Saito, I Iwamoto.   

Abstract

To study the activation states and cytokine profiles of pulmonary T cells in corticosteroid-resistant and corticosteroid-sensitive interstitial pneumonitis (IP) in dermatomyositis (DM)/polymyositis (PM), we examined the activation markers and cytokine profiles of T cells in bronchoalveolar lavage fluids (BALF) from patients with IP in DM/PM before prednisolone therapy and then compared the activation states of T cells according to the therapeutic response of IP to prednisolone therapy. CD25+ CD4+ T cells in BALF were significantly increased in both corticosteroid-resistant and corticosteroid-sensitive IP in DM/PM as compared with those in controls without IP. Furthermore, CD25+ CD4+ T cells in BALF were significantly more increased in corticosteroid-resistant IP than those in cortico teroid- sensitive IP. Moreover, CD25+ CD8+ T cells in BALF were significantly increased only in corticosteroid-resistant IP, but not in corticosteroid-sensitive IP or controls without IP. IFN-gamma mRNA was detected in BALF T cells in corticosteroid-resistant and corticosteroid-sensitive IP but not in controls without IP, whereas IL-4 mRNA was virtually undetected in BALF T cells in both the IP groups. However, there were no significant differences in CD4/CD8 ratio of BALF T cells, HLA-DR+ BALF T cells or CD25+ and HLA-DR+ peripheral blood T cells between the two IP groups. These results indicate that activated Th1-type pulmonary T cells play an important role in the development of corticosteroid- resistant IP in DM/PM and that the increase in CD25+ CD8+ T cells in BALF is a useful indicator for corticosteroid-resistant IP in DM/PM and hence may be an indicator for early use of cyclosporin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197897      PMCID: PMC1906473          DOI: 10.1046/j.1365-2249.2002.01933.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Workshop summary and guidelines: investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airway diseases.

Authors: 
Journal:  J Allergy Clin Immunol       Date:  1991-11       Impact factor: 10.793

2.  Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings.

Authors:  H D Tazelaar; R W Viggiano; J Pickersgill; T V Colby
Journal:  Am Rev Respir Dis       Date:  1990-03

3.  Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.

Authors:  G Feutren; M J Mihatsch
Journal:  N Engl J Med       Date:  1992-06-18       Impact factor: 91.245

4.  Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO- and CD45RO+ subsets.

Authors:  V Brinkmann; C Kristofic
Journal:  J Immunol       Date:  1995-10-01       Impact factor: 5.422

5.  Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis?

Authors:  K Maeda; R Kimura; K Komuta; T Igarashi
Journal:  Scand J Rheumatol       Date:  1997       Impact factor: 3.641

Review 6.  Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis.

Authors:  W B Gruhn; J A Diaz-Buxo
Journal:  J Rheumatol       Date:  1987-10       Impact factor: 4.666

7.  Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance.

Authors:  A L Katzenstein; R F Fiorelli
Journal:  Am J Surg Pathol       Date:  1994-02       Impact factor: 6.394

8.  Macrophage priming by interferon gamma: a selective process with potentially harmful effects.

Authors:  J G Williams; G J Jurkovich; G B Hahnel; R V Maier
Journal:  J Leukoc Biol       Date:  1992-12       Impact factor: 4.962

9.  Rescue of thymocytes and T cell hybridomas from glucocorticoid-induced apoptosis by stimulation via the T cell receptor/CD3 complex: a possible in vitro model for positive selection of the T cell repertoire.

Authors:  M Iwata; S Hanaoka; K Sato
Journal:  Eur J Immunol       Date:  1991-03       Impact factor: 5.532

10.  Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes.

Authors:  M Brunetti; N Martelli; A Colasante; M Piantelli; P Musiani; F B Aiello
Journal:  Blood       Date:  1995-12-01       Impact factor: 22.113

View more
  18 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

2.  Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis.

Authors:  Eishi Miyazaki; Masaru Ando; Tomoko Muramatsu; Tetsujiro Fukami; Osamu Matsuno; Shin-Ichi Nureki; Takuya Ueno; Tomiyasu Tsuda; Toshihide Kumamoto
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

3.  Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease.

Authors:  Thomas J Richards; Aaron Eggebeen; Kevin Gibson; Samuel Yousem; Carl Fuhrman; Bernadette R Gochuico; Noreen Fertig; Chester V Oddis; Naftali Kaminski; Ivan O Rosas; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2009-07

Review 4.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 5.  Treatment in myositis.

Authors:  Chester V Oddis; Rohit Aggarwal
Journal:  Nat Rev Rheumatol       Date:  2018-03-29       Impact factor: 20.543

6.  Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis.

Authors:  Dong Xue Wang; Xin Lu; Ning Zu; Bing Lin; Li Ying Wang; Xiao Ming Shu; Li Ma; Guo Chun Wang
Journal:  Clin Rheumatol       Date:  2012-08-30       Impact factor: 2.980

7.  Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients.

Authors:  Lichong Shen; Qingran Yan; Xiaoxiang Chen
Journal:  Arch Rheumatol       Date:  2019-08-26       Impact factor: 1.472

8.  Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.

Authors:  Dong Jin Go; Jin Kyun Park; Eun Ha Kang; Hyun Mi Kwon; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Rheumatol Int       Date:  2015-07-30       Impact factor: 2.631

Review 9.  T cells in myositis.

Authors:  Vivianne Malmström; Paulius Venalis; Inka Albrecht
Journal:  Arthritis Res Ther       Date:  2012-12-28       Impact factor: 5.156

10.  Phenotypes of Peripheral Blood Lymphocytes and Cytokine Expression in Polymyositis and Dermatomyositis before Treatment and after Clinical Remission.

Authors:  Yasuhiro Shimojima; Wataru Ishii; Masayuki Matsuda; Shu-Ichi Ikeda
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2012-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.